Earnings summaries and quarterly performance for Seres Therapeutics.
Executive leadership at Seres Therapeutics.
MT
Marella Thorell
Detailed
Co-Chief Executive Officer and Chief Financial Officer
CEO
Thomas DesRosier
Detailed
Co-Chief Executive Officer and Chief Legal Officer
CEO
MH
Matthew Henn
Detailed
Executive Vice President and Chief Scientific Officer
TY
Teresa Young
Detailed
Executive Vice President, Chief Commercial and Strategy Officer
Board of directors at Seres Therapeutics.
Research analysts who have asked questions during Seres Therapeutics earnings calls.
Joseph Thome
TD Cowen
4 questions for MCRB
Also covers: ALKS, AMLX, ARDX +12 more
Caroline Kimberly Pocher
JPMorgan Chase & Co.
3 questions for MCRB
Also covers: XENE
ET
Edward Tenthoff
Piper Sandler Companies
2 questions for MCRB
Also covers: ARVN, ARWR, CAPR +14 more
JN
John Newman
Canaccord Genuity Group Inc.
2 questions for MCRB
Also covers: ALLO, ATRA, BNTX +4 more
Recent press releases and 8-K filings for MCRB.
PsiThera Secures Series A Financing and Appoints New CEO
MCRB
CEO Change
New Projects/Investments
- PsiThera announced the close of a $47.5 million Series A financing round, led by Samsara Biocapital and Lightstone Ventures.
- Eric Shaff has been appointed as the new Chief Executive Officer of PsiThera, joining the established leadership team.
- The company is advancing a pipeline of novel therapeutics, with initial programs focused on the Tumor Necrosis Factor (TNF) superfamily, utilizing its QUAISAR™ computational intelligence platform to develop oral drugs for immune and inflammatory diseases.
Dec 10, 2025, 12:00 PM
Seres Advances SER-155 Phase 2 Development and Outlines Commercial Opportunity
MCRB
New Projects/Investments
Guidance Update
- Seres is progressing SER-155, a microbiome therapy for allogeneic hematopoietic stem cell transplant (Allo-HSCT) patients, which has received Breakthrough Therapy designation. Phase 1B data indicated a 77% relative risk reduction in bloodstream infection.
- The company plans a Phase 2 study for SER-155 involving 248 patients, with an interim analysis anticipated approximately 12 months after study commencement that could lead to discussions with the FDA regarding a pivotal study.
- The commercial opportunity for SER-155 in Allo-HSCT is substantial, targeting 40,000 annual global transplants, and the product's value proposition supports a premium price in the range of $25,000-$27,000, similar to PREVYMIS.
- Seres's financial resources, including over $50 million from recent ATM usage, are projected to fund operations through Q2 of next year, with primary focus on preparatory activities for the SER-155 Phase 2 study.
Dec 2, 2025, 3:30 PM
Seres Discusses Pipeline Progress and Financial Runway
MCRB
New Projects/Investments
Guidance Update
- Seres is advancing SER-155 for allogeneic hematopoietic stem cell transplant (allo-HSCT) patients, with a Phase II study estimated to enroll 248 patients and an interim analysis planned approximately 12 months after study commencement, which could potentially lead to a registrational study.
- The SER-155 program has a significant commercial opportunity, targeting 40,000 annual global transplants and potentially commanding a premium price comparable to Merck's PREVYMIS, which is priced around $25,000-$27,000.
- Seres is engaged in partnership discussions for SER-603, a program for ulcerative colitis and Crohn's disease, aiming for a research collaboration to deploy biomarkers and potentially boost efficacy and durability of combination therapies.
- The company ended Q3 with $48 million in cash, subsequently increasing to over $50 million through an ATM, providing funding through the second quarter of next year.
Dec 2, 2025, 3:30 PM
Seres Therapeutics Provides Update on SER-155 Clinical Development and Financial Runway
MCRB
New Projects/Investments
Guidance Update
- Seres Therapeutics is developing SER-155 for allogeneic hematopoietic stem cell transplant (Allo-HSCT) patients, which demonstrated a 77% relative risk reduction in bloodstream infection in its Phase 1B study.
- The company is preparing for a Phase 2 study for SER-155, estimated to enroll 248 patients, with an interim analysis anticipated 12 months after study initiation.
- The commercial opportunity for SER-155 in Allo-HSCT is significant, targeting 40,000 annual global transplants and addressing high costs associated with infections, which can add an incremental $200,000 per patient.
- Seres ended Q3 with $48 million and, with additional ATM funding, now has over $50 million, projected to fund operations through Q2 of next year.
Dec 2, 2025, 3:30 PM
Seres Therapeutics Reports Q3 2025 Net Income and Strategic Updates
MCRB
Earnings
New Projects/Investments
Layoffs
- Seres Therapeutics reported a net income from continuing operations of $8.2 million in Q3 2025, primarily due to a $27.2 million gain on the sale of VAST, which included a $25 million installment payment from Nestlé.
- As of September 30, 2025, the company held $47.6 million in cash and cash equivalents and expects to fund operations through the second quarter of 2026.
- The immediate priority is advancing SER-155 into a Phase 2 study, with FDA alignment on the protocol, but its commencement is funding-dependent. Interim analysis results are anticipated within 12 months of study initiation.
- The company implemented targeted cost reduction measures, including a workforce reduction of approximately 25%, to extend its cash runway and focus resources. Seres is actively seeking additional capital or R&D partnerships.
- Initial clinical results from an investigator-sponsored study evaluating SER-155 in immune checkpoint inhibitor-related enterocolitis (IREC) are expected in early 2026.
Nov 5, 2025, 1:30 PM
Seres Therapeutics Reports Q3 2025 Financial Results and Business Updates
MCRB
Earnings
Guidance Update
New Projects/Investments
- Seres Therapeutics reported net income from continuing operations of $8.2 million for the third quarter of 2025, compared to a net loss of $51.0 million in the prior year period, primarily due to a $27.2 million gain on the sale of VOWST.
- As of September 30, 2025, the company had $47.6 million in cash and cash equivalents and expects to fund operations through the second quarter of 2026.
- Operating expenses decreased in Q3 2025, with Research and Development expenses at $12.6 million and General and Administrative expenses at $9.5 million, reflecting cost-reduction measures implemented during the quarter.
- The company is finalizing the SER-155 Phase 2 study protocol following FDA feedback and is actively seeking capital to support the study, with interim clinical results expected within 12 months of study initiation once funding is secured.
Nov 5, 2025, 12:05 PM
Seres Provides Update on SER-155 Program and Financial Position
MCRB
M&A
New Projects/Investments
Guidance Update
- Seres completed the VOWST asset sale to Nestle Health Science in September 2024, which provided capital and extended the operational runway. The company received $50M in January 2025 and $25M in July 2025 from this transaction.
- The SER-155 Phase 1b data showed a 77% relative risk reduction for bloodstream infections and a well-tolerated safety profile in allo-HSCT patients. SER-155 received Breakthrough Therapy designation in December 2024.
- Planning for the SER-155 Phase 2 study is ongoing, with the protocol being finalized based on FDA feedback, and commencement is funding dependent. The study aims to enroll 248 patients, with interim data anticipated within 12 months of study start.
- As of September 30, 2025, Seres had approximately $47.6M in cash and cash equivalents, projecting a cash runway through Q2 2026.
Nov 4, 2025, 11:00 PM
Quarterly earnings call transcripts for Seres Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more